Italia markets close in 2 hours 44 minutes

Aeterna Zentaris Inc. (AEZS.TO)

Toronto - Toronto Prezzo in tempo reale. Valuta in CAD.
Aggiungi a watchlist
5,15+0,19 (+3,83%)
Alla chiusura: 03:54PM EST
Schermo intero
Chiusura precedente4,96
Aperto5,13
Denaro5,09 x 0
Lettera5,15 x 0
Min-Max giorno5,13 - 5,15
Intervallo di 52 settimane4,00 - 13,50
Volume704
Media Volume2.091
Capitalizzazione25,008M
Beta (5 anni mensile)1,66
Rapporto PE (ttm)N/D
EPS (ttm)-0,10
Prossima data utili27 mar 2023 - 31 mar 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendo11 ago 1999
Stima target 1AN/D
  • GlobeNewswire

    Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones

    Aeterna Zentaris focused on accelerating recruitment for ongoing DETECT trial and efforts to partner rights to Macrilen™ in the U.S. and CanadaCompany continues to build growing body of data across its development pipeline, advancing towards go/no-go decision milestones at each stage to establish prioritization and drive momentumStrategic decision to streamline development programs by discontinuing the Company’s early-stage vaccine programs provides Aeterna Zentaris with an expected extended cas

  • GlobeNewswire

    Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event

    Live video webcast on Thursday, January 19th at 3:00 PM ET TORONTO, ONTARIO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 1

  • GlobeNewswire

    Aeterna Zentaris Reports Third Quarter 2022 Financial Results

    – Company ended the quarter with $53.8 million in cash – Driving continued progress across diversified pre-clinical and clinical development pipeline TORONTO, ONTARIO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (Nasdaq: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the third quarter ended Sept